https://www.mskcc.org/news/fda-grants-breakthrough-therapy-designation-cobimetinib-mek-inhibition-histiocytic-neoplasms-research-led-msk
FDA Grants Breakthrough Therapy Designation to Cobimetinib for MEK Inhibition in Histiocytic...
Memorial Sloan Kettering Cancer Center (MSK) announced today that the US Food and Drug Administration (FDA) has granted a Breakthrough Therapy Designation to...
breakthrough therapyfdagrantsdesignationcobimetinib